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Frontotemporal dementia (FTD) and amyotrophic
lateral sclerosis (ALS) are devastating neurodegener-
ative disorders with clinical, genetic, and neuropath-
ological overlap. Hexanucleotide (GGGGCC) repeat
expansions in a noncoding region of C9ORF72
are the major genetic cause of FTD and ALS
(c9FTD/ALS). The RNA structure of GGGGCC
repeats renders these transcripts susceptible to an
unconventional mechanism of translation—repeat-
associated non-ATG (RAN) translation. Antibodies
generated against putative GGGGCC repeat RAN-
translated peptides (anti-C9RANT) detected high
molecular weight, insoluble material in brain homog-
enates, and neuronal inclusions throughout the CNS
of c9FTD/ALS cases. C9RANT immunoreactivity was
not found in other neurodegenerative diseases,
including CAG repeat disorders, or in peripheral
tissues of c9FTD/ALS. The specificity of C9RANT
for c9FTD/ALS is a potential biomarker for this
most common cause of FTD and ALS. These findings
have significant implications for treatment strategies
directed at RAN-translated peptides and their aggre-
gation and the RNA structures necessary for their
production.
INTRODUCTION
Frontotemporal dementia (FTD) and amyotrophic lateral scle-
rosis (ALS) are devastating diseases with no effective treatment.
FTD, a common cause of early-onset dementia, encompasses
a group of disorders distinguished clinically by abnormalities in
behavior, language, and personality, while ALS is characterized
by the degeneration of motor neurons, leading tomuscle atrophy
and paralysis. Because of significant clinical and neuropatholog-
ical overlap, FTD and ALS are thought to represent a diseasespectrum (Van Langenhove et al., 2012). Frontal lobe impairment
is increasingly recognized in ALS (Phukan et al., 2012) and
a subset of FTD patients develops features of motor neuron
disease. Furthermore, most ALS cases and the most common
pathological subtype of FTD (FTLD-TDP) are associated with
neuronal and glial TDP-43-positive inclusions (Neumann et al.,
2006). Two independent groups recently identified a hexanucleo-
tide (GGGGCC) repeat expansion in a noncoding region of
C9ORF72 as the most frequent genetic cause of ALS and FTD
(c9FTD/ALS) (DeJesus-Hernandez et al., 2011; Renton et al.,
2011), firmly establishing a genetic link between the two
disorders. In addition to TDP-43 inclusions, a characteristic
finding of c9FTD/ALS is the presence of TDP-43-negative,
p62/sequestosome-1-positive neuronal inclusions in the cere-
bellum and hippocampus (Al-Sarraj et al., 2011; Pikkarainen
et al., 2010). These inclusions are also immunoreactive for
ubiquitin and select ubiquitin-binding proteins, most notably
ubiquilin-2 (Bieniek et al., 2013; Brettschneider et al., 2012).
While the mechanisms of disease of c9FTD/ALS remain
unknown, several groups have shown that mRNA levels of at
least one C9ORF72 transcript are decreased in c9FTD/ALS
(DeJesus-Hernandez et al., 2011; Gijselinck et al., 2012; Renton
et al., 2011), suggesting a potential loss of function. While the
normal function of the C9ORF72 protein remains obscure, it is
structurally related to DENN domain proteins, highly conserved
GDP-GTP exchange factors for Rab GTPases (Levine et al.,
2013; Zhang et al., 2012).The accumulation of RNA transcripts
containing the GGGGCC repeat within nuclear foci in frontal
cortex and spinal cord in c9FTD/ALS also suggests a toxic
RNA gain of function (DeJesus-Hernandez et al., 2011). RNA
foci, which lead to the sequestration and altered activity of
RNA-binding proteins, have been implicated in several non-
coding expansion disorders (Renoux and Todd, 2012). Another
possible pathogenic mechanism is repeat associated non-ATG
translation (RAN translation). RAN translation, an unconventional
mode of translation that occurs in the absence of an initiating
ATG codon, was first described by Ranum and coworkers
(Zu et al., 2011), who reported that RAN translation across
expanded CAG repeats occurs in all reading frames (CAG,
AGC, and GCA) to produce homopolymeric proteins of longNeuron 77, 639–646, February 20, 2013 ª2013 Elsevier Inc. 639
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Translation of c9FTD/ALS GGGGCC Repeatspolyglutamine, polyserine, or polyalanine tracts. Of particular
importance, polyalanine and polyglutamine proteins, respec-
tively, were found to accumulate in disease-relevant tissues of
patients with spinocerebellar ataxia type 8 and myotonic
dystrophy type 1 (Zu et al., 2011).
Given that canonical rules of translation may not apply in
disorders associated with repeat expansions, we sought to
determine whether RAN translation products of expanded
GGGGCC are produced in c9FTD/ALS. Three two-amino acid
alternating copolymers—(glycine-alanine)n, (glycine-arginine)n,
and (glycine-proline)n—could theoretically be expressed by
RAN translation of the sense transcript of the expanded
GGGGCC repeat in C9ORF72. To explore this possibility, we
generated polyclonal antibodies with high specificity and sensi-
tivity to putative RAN translation products and have identified
a novel neuropathology specific to c9FTD/ALS.
RESULTS
The detection of nuclear foci containing RNA transcripts contain-
ing the expanded GGGGCC repeat in cortical and spinal cord
neurons of c9FTD/ALS cases (DeJesus-Hernandez et al., 2011)
indicates that these transcripts are expressed and thus possibly
available for RAN translation. Given evidence that RAN transla-
tion of expanded CAG repeats depends on hairpin formation
(Zu et al., 2011), we sought to determine the structure of
expanded GGGGCC repeats using the latest methodologies
for generating secondary structure predictions (SSPs) (Gardner
et al., 2011). Shown in Figure S1A, available online, is the major
RNA SSP for ten GGGGCC repeats (60 bases). For comparison,
the SSP for 20 repeats (60 bases) of the CAG trinucleotide is
shown. Note that both structures form stable hairpins, with the
GGGGCC repeat structure having a lower composite global
energy (DG = 40.80 kcal/mol), and thus greater stability, than
CAG repeats of equal length (DG = 19.60). In fact, GGGGCC
repeats become successively more stable as repeat length
increases, having a DG of 242.80 and 1,000.30 kcal/mol for
repeats of 300 and 1,200 bases, respectively. Given these obser-
vations, the GGGGCC repeat may be subject to RAN translation.
To elucidate whether RAN translation products are indeed
expressed in c9FTD/ALS, we generated two independent poly-
clonal antibodies (termed anti-C9RANT) by immunizing two
rabbits using the pooled synthetic peptides (GA)8, (GP)8, and
(GR)8 as antigens. These peptides were chosen because RAN
translation of (GGGGCC)n transcripts in the three alternate
reading frames would produce poly-(glycine-alanine), poly-
(glycine-proline), andpoly-(glycine-arginine) peptides (Figure 1A).
To determine selectivity of both C9RANT antibodies to
glycine-alanine, glycine-proline, and glycine-arginine tracts, we
performed quantitative indirect immunoassays using Meso
Scale Discovery (MSD) electrochemiluminescence detection
technology. Measurement of anti-C9RANT binding to immobi-
lized (GA)8, (GP)8, or (GR)8 peptides shows that both anti-
C9RANT antibodies bound the (GP)8 peptide in a dose-
dependent manner, with relatively little binding to (GA)8 and
(GR)8 and no binding to the negative control peptides (GK)8
and (GX)8 (Figures 1B and 1C). Consistent with these findings,
anti-C9RANT selectively detected exogenously expressed640 Neuron 77, 639–646, February 20, 2013 ª2013 Elsevier Inc.GFP-tagged (GP)5 in HeLa cell lysates, as assessed by western
blot (Figure S1B). Immunofluorescence staining of HeLa cells
transfected to express the various GFP-tagged peptides also
showed that (GP)5 was immunoreactive for anti-C9RANT, but
not (GA)5 or (GR)5 or the negative controls (GK)5 and (GX)5 (Fig-
ure S1C). GFP-tagged (GP)5, (GR)5, and (GA)5 were expressed
in the cytoplasm and nucleus of cells. Of note, (GP)5 and (GR)5
assembled into punctate structures in the cytoplasm, whereas
(GA)5 expression remained diffuse. These results show the
generation of two C9RANT polyclonal antibodies that preferen-
tially detect poly-(glycine-proline) peptides.
To evaluate whether RAN translation products are expressed
in c9FTD/ALS, we performed western blot analysis of urea
fractions from cerebellar tissue of FTLD and ALS cases with or
without expanded GGGGCC repeats. Cerebellar tissue was
utilized in view of the cerebellar pathology observed in c9FTD/
ALS. Notably, insoluble anti-C9RANT-immunoreactive high
molecular weight material was observed only in samples from
C9ORF72 mutation carriers (Figure 1D, arrow). Due to the large
size of these products, they became trapped at the top of the
stacking gel. To overcome this issue, we conducted dot blots
using the cerebellar urea fractions. Anti-C9RANT-immunoreac-
tivity was specific to c9FTD/ALS and was not detected in cases
lacking pathogenic repeat expansions in C9ORF72 (Figure 1E
and Figure S1D). Consistent with these findings, immunohisto-
chemical analysis revealed that anti-C9RANT-immunoreactive
neuronal cytoplasmic inclusions were abundant in the cere-
bellum of c9FTD/ALS cases (Figures 1F and 1H) but absent in
FTLD-TDP cases with no C9ORF72 repeat expansion (Figures
1G and 1I). Note that the C9RANT antibodies generated from
two independent rabbits showed similar staining profiles.
For consistency, subsequent immunohistochemical studies
were conducted using the antibody (Rb5823) with the least
background.
The above results indicate that poly-(glycine-proline) peptides
are specifically expressed in c9FTD/ALS. To evaluate whether
their production results from the translation of expanded
GGGGCC repeats in the absence of an ATG-initiating codon,
we sequenced DNase1-treated pre-mRNA collected from cere-
bellar tissue of two c9FTD and two control cases. Sequences
obtained matched the previously reported C9ORF72 genomic
sequence (AL451123.12). The ATG nearest to the GGGGCC
repeat was observed 247 base pairs upstream; however,
multiple stop codons within each frame are present in the 240
base pairs upstream of the repeat, thus placing stop codons
between the ATG and the expanded repeat.
Next, the regional distribution of C9RANT immunoreactivity
within the CNS of c9FTD/ALS cases was assessed by immuno-
histochemistry, revealing widespread neuronal cytoplasmic and
intranuclear inclusions (Figure 2). The inclusions were morpho-
logically similar to TDP-43-negative inclusions noted in previous
studies with ubiquitin or ubiquitin binding (p62 and ubiquilin-2)
immunohistochemistry (Al-Sarraj et al., 2011; Bigio et al.,
2012). C9RANT-immunoreactive inclusions were exclusively
found in gray matter and within neurons. They were not detected
in vascular endothelial or smooth muscle cells or in white matter
or glia. Nonetheless, given the growing recognition of inter-
cellular communication in neurodegeneration (Garden and La
Figure 1. Anti-C9RANT Immunoreactivity Is Specific to c9FTD/ALS
(A) Schematic representation of the possible protein products generated by RAN translation of expandedGGGGCC repeats in the three alternate reading frames.
(B and C) Immunoreactivity of each anti-C9RANT antibody (Rb5822 and Rb5823) toward indicated peptides was measured by adsorbing peptides onto carbon
electrodes in 96-well MSD plates and coincubating wells with anti-C9RANT and a SULFO-tagged anti-rabbit secondary antibody. Anti-C9RANT binding to
respective peptides was quantified by measuring the intensity of emitted light upon electrochemical stimulation of the plate using the MSD Sector Imager 2400.
The amino acid sequence for (GX)5 is Gly-Met-Gly-Asp-Gly-Ser-Gly-Leu-Gly-Thr. (D) Western blot analysis of cerebellar tissue urea fractions from C9ORF72
repeat expansion and nonexpansion FTLD cases using anti-C9RANT. Note the high molecular weight product (arrow). (E) Anti-C9RANT immunoreactivity in
cerebellar urea fractions from FTLD-TDP and ALS cases with or without expanded GGGGCC repeats, as assessed by dot blot. Each dot represents one case.
See also Figure S1. (F–I) Immunohistochemistry with each anti-C9RANT antibody revealed that abundant neuronal inclusion in the cerebellum of c9FTD (F andH),
but not in sporadic FTLD-TDP (G and I). C9RANT-immunoreactive lesions were granular neuronal cytoplasmic inclusions (seen clearly in the Purkinje cell shown in
insets in F and H). Scale bar represents 50 mm in main images and 20 mm in insets.
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Figure 2. Regional Neuropathology of
C9RANT
(A–P) C9RANT-immunoreactive neuronal inclu-
sions were observed throughout the CNS, includ-
ing cerebellum (A, cerebellar molecular layer; B,
cerebellar Purkinje cell layer; C, cerebellar internal
granular layer), neocortex (D, frontal cortex; E,
temporal cortex; F, motor cortex), subcortical gray
matter (G, amygdala; H, dentate gyrus of the
hippocampus; I, CA3 of the hippocampus; J,
lateral geniculate nucleus; K, lateral thalamus; L,
medial geniculate nucleus; N, globus pallidus; O,
hypothalamus; P, nucleus basalis of Meynert), and
to a lesser extent the brainstem (M, substantia
nigra). (Q) Semiquantitative pathology scoring in
these aforementioned regions and in the entorhinal
cortex, medulla, putamen, midbrain, and spinal
cord reveals variable C9RANT-immunoreactive
inclusions throughout the CNS. Cbl, cerebellum;
ctx, cortex; Hp, hippocampus; MB, midbrain; S,
substantia; SC, spinal cord; Subthal, subthalamic;
Thal, thalamus.
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was validated by double-labeled immunofluorescence analysis
of c9FTD hippocampal tissue (Figure 3).The granular cyto-
plasmic and intranuclear inclusions were found in neuronal
populations immunopositive for microtubule-associated protein
2 (MAP2) but not in astrocytes immunopositive for glial fibrillary
acidic protein (GFAP).
Neuronal cytoplasmic inclusions immunoreactive for anti-
C9RANT were coarsely granular and sometimes ‘‘star shaped’’
(Figure 2). In contrast, neuronal intranuclear inclusions were
small round lesions (Figure 4A). C9RANT-immunoreactive inclu-642 Neuron 77, 639–646, February 20, 2013 ª2013 Elsevier Inc.sions were frequent in granular neurons
(e.g., dentate gyrus of hippocampus and
internal granular cell layer of cerebellum;
Figures 2C and 2H) but were also de-
tected in large neurons (e.g., pyramidal
neurons in the neocortex and cerebellar
Purkinje cells; Figures 2B and 2I). The
frequency of C9RANT-immunoreactive
neuronal inclusions in any given region
was variable. To gain an understand-
ing of the distribution, we scored the
density of lesions in 24 brain regions of
30 cases of c9FTD/ALS (Figure 2Q).
Inclusions were detected in most abun-
dance in regions previously shown to be
affected in c9FTD/ALS with p62 immuno-
histochemistry, including the neocortex,
hippocampus, and cerebellum (Pikkarai-
nen et al., 2008, 2010), but they were
also present in regions not previously
considered to be affected, such asmedial
and lateral geniculate nuclei (Figure 2Q).
The lesion burden tended to be greater
in limbic structures (e.g., hippocampusand amygdala) and neocortex than in subcortical gray matter
and brainstem, but the most severely affected region in most
cases was the cerebellar cortex.
To further determine specificity of C9RANT immunoreactivity
for c9FTD/ALS, we performed immunohistochemistry on hippo-
campus and cerebellum of 44 FTLD-TDP and 6 ALS cases lack-
ing the C9ORF72 repeat expansion, as well as 65 cases with
other neurodegenerative diseases (Alzheimer’s disease, diffuse
Lewy body disease [some of which presented clinically as
Parkinson’s disease and dementia], multiple system atrophy,
progressive supranuclear palsy, and corticobasal degeneration)
Figure 3. C9RANT-Immunoreactive Inclu-
sions Are Present in Neurons but Not
Astrocytes
Double-label immunofluorescencewas performed
on hippocampal tissue from a c9FTD case using
anti-C9RANT (Rb5823) antiserumand theneuronal
marker MAP2 or the astrocytic marker GFAP. Note
that C9RANT-immunoreactive inclusions localize
exclusively to neurons (A) and are not found in
astrocytes (B). Scale bar represents 50 mm.
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noreactive lesions (Figure S2). Given that RAN translation is
reported in other repeat disorders (Zu et al., 2011), we also per-
formed immunohistochemistry on vulnerable brain regions in
Huntington disease (basal ganglia), spinocerebellar ataxia type
3 (pons), and Kennedy’s spinal and bulbar muscular atrophy
(medulla). All cases had characteristic neuronal intranuclear
inclusions with p62 immunohistochemistry, but none had
C9RANT-immunoreactive neuronal inclusions in either nucleus
or cytoplasm (Figures 4A–4H).
Given the specificity of anti-C9RANT for neuronal inclusions
throughout the CNS of c9FTD/ALS, it was of interest to know
whether lesions would be detected in peripheral tissues.
Sections from skeletal muscle, peripheral nerve, dorsal root
ganglia, heart, lung, liver, spleen, kidney, and testes were pro-
cessed for C9RANT immunohistochemistry from three c9FTD/
ALS cases and a sporadic FTLD-TDP case (Figures 4I–4L).
No C9RANT-immunoreactive inclusions were detected in other
organs, including peripheral nerves and ganglia. The only
exception was the testes, where C9RANT immunoreactivity
was detected in both cytoplasmic and nuclear inclusions in
Sertoli cells, but not in germ cells of the seminiferous tubules
(Figure 4L) in the c9FTD/ALS cases and not the FTLD-TDP
case.
DISCUSSION
The discovery of a neuropathology specific to c9FTD/ALS,
namely the accumulation of poly-(glycine-proline) peptides,
provides insight into the pathobiology of c9FTD/ALS. While it
remains to be determined whether polypeptides generated by
RAN translation are neurotoxic, the findings herein expand the
possible mechanisms of disease in c9FTD/ALS. Our findings
show C9RANT-immunoreactive lesions in both neuronal popu-
lations that are generally not affected in neurodegenerative
disease processes (e.g., neurons of lateral geniculate nucleus),
as well as in vulnerable areas (e.g., neurons of neocortex and
hippocampus).
The initiation of RAN translation is thought to depend on RNA
hairpin structures that utilize C:G complementary pairing. Long
tracts of CAG repeats that form hairpins and multibranched
structures undergo RAN translation, whereas CAA repeats ofNeuron 77, 639–646,similar length do not form hairpins and
are not RAN translated (Zu et al., 2011).
Using established methods for pre-
dicting the RNA secondary structure ofGGGGCC repeats, we found that an imperfect double-
stranded-like conformation is energetically preferred, similar to
our prediction models for CAG repeat RNA and to CAG repeat
structures previously derived by alternative methods (de Mezer
et al., 2011). GGGGCC RNA transcripts are therefore likely to
form stable hairpins and, consequently, may undergo RAN
translation. Nonetheless, it must be noted that the precise RNA
structural features involved in RAN translation initiation remain
to be fully elucidated.
To determine whether there is evidence of RAN translation in
c9FTD/ALS, we immunized two rabbits with pooled (GA)8,
(GP)8, and (GR)8 peptides. Using a variety of approaches, we
show that both C9RANT antibodies preferentially detect poly-
(glycine-proline), having little or no immunoreactivity toward
poly-(glycine-arginine) or poly-(glycine-alanine), depending on
the assay employed. Of importance, anti-C9RANT antibodies
had disease specificity, showing binding to neuronal inclu-
sions in c9FTD/ALS, but not to neuronal or glial inclusions in
a range of other common neurodegenerative diseases or to
intranuclear inclusions in several CAG trinucleotide repeat
disorders. Additional screening of other repeat disorders would
be important, since the number of cases of trinucleotide repeat
disorders screened for C9RANT-immunoreactive pathology
was small. The biochemical correlate of C9RANT-positive
inclusions was high molecular weight and insoluble material
comparable to that present in other disorders with insoluble
neuronal inclusions, most notably tau in Alzheimer’s disease.
This insoluble material was present in homogenates from
brain regions with dense C9RANT-immunoreactive pathology,
in particular the cerebellum, of c9FTD/ALS cases, but not in
ALS or FTLD cases negative for the C9ORF72 expanded
repeat.
C9RANT immunoreactivity was, with the exception of testes,
specific to the CNS, despite the fact that wild-type C9ORF72
transcripts are expressed in peripheral tissues (DeJesus-
Hernandez et al., 2011). It is interesting to note that the semi-
quantitative PCRs suggest that expression levels of GGGGCC-
containing transcript are highest in the brain and testes, the
same regions where C9RANT immunoreactivity is observed.
Conversely, the short transcript variant, which is not predicted
to contain the GGGGCC sequence, is expressed equally in
CNS and peripheral tissues.February 20, 2013 ª2013 Elsevier Inc. 643
Figure 4. Specificity of C9RANT Pathology
p62 immunolabeling of neuronal intranuclear inclusions (arrows) in c9FTD/ALS (A, cerebellum), Huntington disease (C, basal ganglia), spinocerebellar ataxia type
3 (E, pons), and spinal and bulbar muscular atrophy (Kennedy’s disease) (G, medulla). Anti-C9RANT-positive inclusions are specific to c9FTD/ALS (B) and absent
from these other CAG repeat disorders (D, Huntington disease; F, spinocerebellar ataxia type 2; H, Kennedy’s disease). Additionally, C9RANT pathology is
predominantly neuronal, with no inclusions in the heart (I), kidney (J), or spleen (K). The only other organ where C9RANT lesions were found was the testes, where
C9RANT-immunoreactive cytoplasmic and nuclear inclusions were noted in Sertoli cells (L). Scale bars in (H) and (L) represent 30 mm; scale bars in (B) and inset of
(L) represent 6 mm. See also Figure S2 and Table S1.
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an encouraging step in the development of a biomarker for
c9FTD/ALS. Although the repeat-primed PCR method to screen
for c9FTD/ALS is fast and cost effective, GGGGCC repeat size
determined using DNA from whole blood may not accurately
reflect repeat size in the brain or spinal cord due to somatic
heterogeneity and varying repeat sizes in different tissues from
a single patient (van Blitterswijk et al., 2012). The development
of anti-C9RANT immunoassays is warranted to investigate
C9RANT immunoreactivity in cerebrospinal fluid as a potential
marker of disease activity and/or progression.
We provide clear evidence that the accumulation of poly-
(glycine-proline) peptides is a pathognomonic feature of
c9FTD/ALS. These results do not, however, rule out the possible
accumulation of other translated products from the expanded
GGGGCC repeat. As mentioned, the alternate frames of sense
GGGGCC RNA may be translated, producing poly-(glycine-
alanine) and poly-(glycine-arginine) peptides. While we cannot
exclude the possibility of ATG-initiated translation of GGGGCC
repeat-containing transcripts, poly-(glycine-proline) peptides
probably result from unconventional translation of the GGGGCC
expansion located in an intronic region of C9ORF72, given that
STOP codons occur in each of the translation frames of the
sense transcript upstream of the repeat. It is also worth noting
that antisense RNA is generated in several repeat disorders
(Renoux and Todd, 2012), and if this phenomenon is reproduced
with theC9ORF72 hexanucleotide expansion, RAN translation of644 Neuron 77, 639–646, February 20, 2013 ª2013 Elsevier Inc.CCCCGG antisense RNA could result in the production of poly-
(proline-alanine), poly-(proline-glycine), and poly-(proline-argi-
nine). Further work is required to discover the existence of the
antisense transcript and the origin of translation initiation.
Given that the abnormal accumulation of insoluble proteins
has been associated with neuronal dysfunction and degenera-
tion in many neurodegenerative diseases, the identification of
disease-specific C9RANT-positive pathology in patients with
a C9ORF72 repeat expansion may offer valuable insight on
disease mechanism and potential therapeutic strategies. Not
only may the abnormal aggregation of RAN translation products
be targeted, but so too could the formation of RNA structures
thought critical for RAN translation.EXPERIMENTAL PROCEDURES
Structure Prediction of GGGGCC Sequences
The SSP for GGGGCC and CAG repeats was modeled using RNA prediction
packages MFOLD, Sfold, and Vienna RNA Package (RNAfold). Details are
provided in the Supplemental Experimental Procedures.Generation of C9RANT Antibodies
Each of two rabbits (Rb5822 and Rb5823) was immunized with the following
three pooled peptides: C-Ahx-(GA)8-amide, C-Ahx-(GP)8-amide, and C-Ahx-
(GR)8-amide. Preimmune serum from each rabbit was tested against peptide
antigens and tissue from c9FTD/ALS cases by immunohistochemistry and
confirmed negative. Antiserum was used directly or purified with Protein A
or G affinity columns.
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Quantitative indirect immunoassays using anti-C9RANT antibodies were per-
formed using the Meso Scale Discovery (MSD) electrochemiluminescence
platform, as described in the Supplemental Experimental Procedures.
Sequential Fractionation and Analysis of Frozen Cerebellar Tissue
Tissues utilized for all experiments within this study were obtained from cases
negative or positive for expanded repeats in C9ORF72, as determined by a
two-step protocol (DeJesus-Hernandez et al., 2011). Protein was sequentially
extracted from frozen cerebellar tissue as previously described by Neumann
et al. (2006). Urea fractions were mixed, but not boiled, in SDS sample buffer
containing 5% b-mercaptoethanol and run on 10% Tris-Glycine Novex gels
(Invitrogen). Samples were transferred to PVDF membranes, blocked in 5%
nonfat dry milk, and probed with anti-C9RANT. For dot blots, urea fractions
(2 ml per sample) were dotted directly to nitrocellulose membrane, which
were then blocked and probed with anti-C9RANT. See the Supplemental
Experimental Procedures for details.
RNA Sequencing Methods
RNA was collected from frozen cerebellar tissue using QIAGEN RNeasy Plus
mini kits with genomic DNA eliminator columns and an additional on column
RNase-free DNase1 treatment. RNA was reverse transcribed to cDNA with
either oligo dTs or random hexamers (Invitrogen). PCR products were ampli-
fied in the pre-mRNA region, upstream of the GGGGCC repeat, using the
forward primer 50- CTACGGTGTCCCGCTAGGAAAG and the reverse primer
50- GGCCCCTAGCGCGCGACTCCTGAG and downstream of the repeat using
the forward primer 50- GGGGCGTGGTCGGGGCGGGCCCGG and the reverse
primer 50- AAGGAGACAGCTCGGGTACTGA. The junction of noncodon
exon 1a to exon 2 in mature transcript variants 1 (NM_145005.5) and 3
(NM_001256054.1) was amplified with the forward primer 50- AAAGATGA
CGCTTGGTGTGTC and the reverse primer 50- TATGAAGTGGGAGGTAGA
AAC. Sequencing of amplicons was performed with the same primers using
Big Dye Terminator v3.1 (Applied Biosciences), cleaned by Montage vacuum
plates (Millipore), analyzed on an ABI3730 (Applied Biosciences), and viewed
with Sequencher software (Gene Codes).
Immunohistochemistry of Central and Peripheral Nervous System
Tissues
Anti-C9RANT (Rb5823) immunoreactivity was examined in postmortem tissue
from 21 FTLD and 9 ALS C9ORF72mutation carriers. Sections from the frontal
and temporal cerebral cortices, hippocampus, cerebellum, basal ganglia,
amygdala, thalamus, midbrain, and spinal cord (if available) were stained
with C9RANT antiserum (1:5,000). In three C9ORF72-linked FTD/ALS cases,
anti-C9RANT pathology from multiple tissue types was examined, including
heart, lung, spleen, liver, kidney, muscle, peripheral nerve, and testis. The
hippocampus or basal forebrain was also studied in 123 control cases,
including 41 sporadic FTLD, 6 sporadic ALS (1 was matched control for the
other organs), 3 FTLD cases due to GRN mutation, 15 Alzheimer’s disease,
15 multiple system atrophy, 15 diffuse Lewy body disease, 14 progressive
supranuclear palsy, 6 corticobasal degeneration disease, 2 Huntington
disease, 1 spinocerebellar ataxia type 3, 1 spinal and bubal muscular atrophy
(Kennedy’s disease), 1 dentato-rubro-pallido-luysian atrophy, and 3 cogni-
tively normal cases. Cases were stained with anti-C9RANT or mouse mono-
clonal p62 (BD Biosciences) using previously published methods (Bieniek
et al., 2013). Deidentified postmortem brain samples used in this study have
been deemed ‘‘exempt’’ as defined by federal regulations for human subject
research. All autopsies were obtained after informed consent of the legal
next of kin, and brain banking procedures conform to ethical guidelines of
theMayo Clinic Institutional Review Board (IRB). See the Supplemental Exper-
imental Procedures for details.
Double-Label Immunofluorescence
Double-label immunofluorescence was performed on hippocampal tissue
from a c9FTD case using anti-C9RANT (Rb5823) antiserum and cell type-
specific antibodies. See the Supplemental Experimental Procedures for
details.SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.neuron.2013.02.004.ACKNOWLEDGMENTS
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